Investigational Drug Information for Tivantinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Tivantinib?
Tivantinib is an investigational drug.
There have been 28 clinical trials for Tivantinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 11th 2011.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Daiichi Sankyo Inc., and Daiichi Sankyo, Inc.
Summary for Tivantinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 951 |
| WIPO Patent Applications | 741 |
| Japanese Patent Applications | 298 |
| Clinical Trial Progress | Phase 3 (2011-01-11) |
| Vendors | 64 |
Recent Clinical Trials for Tivantinib
| Title | Sponsor | Phase |
|---|---|---|
| TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) | Istituto Oncologico Veneto IRCCS | Phase 2 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Medpace, Inc. | Phase 1 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Daiichi Sankyo Inc. | Phase 1 |
Clinical Trial Summary for Tivantinib
Top disease conditions for Tivantinib
Top clinical trial sponsors for Tivantinib
US Patents for Tivantinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
